Novo Nordisk A/S $NVO Stock Holdings Raised by Stratos Wealth Advisors LLC

Stratos Wealth Advisors LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 26.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 3,928 shares of the company’s stock after purchasing an additional 832 shares during the period. Stratos Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $271,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of NVO. Revolve Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Novo Nordisk A/S by 9.6% in the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock worth $657,000 after purchasing an additional 827 shares during the last quarter. PFG Investments LLC increased its position in shares of Novo Nordisk A/S by 1.0% in the 1st quarter. PFG Investments LLC now owns 18,102 shares of the company’s stock worth $1,257,000 after purchasing an additional 178 shares during the last quarter. Live Oak Private Wealth LLC increased its position in shares of Novo Nordisk A/S by 65.0% in the 1st quarter. Live Oak Private Wealth LLC now owns 25,730 shares of the company’s stock worth $1,787,000 after purchasing an additional 10,137 shares during the last quarter. Finally, Flagship Harbor Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 13.1% in the 1st quarter. Flagship Harbor Advisors LLC now owns 14,135 shares of the company’s stock valued at $982,000 after buying an additional 1,636 shares during the period. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of several research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. TD Cowen decreased their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 19th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $76.00.

Novo Nordisk A/S Trading Up 2.6%

Novo Nordisk A/S stock opened at $55.78 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average price of $56.36 and a two-hundred day moving average price of $62.64. The firm has a market capitalization of $249.04 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 2.50 and a beta of 0.68. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $117.96.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.